Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Published:2024-09 Issue: Volume: Page:
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Cook Gordon,Ashcroft A John,Senior Ethan,Olivier Catherine,Hockaday Anna,Richards Jeanine,Cavenagh Jamie D,Snowden John A,Drayson Mark T,de Tute Ruth,Roberts Lesley,Owen Roger G,Yong Kwee,Garg Mamta,Boyd Kevin,Sati Hamdi,Gillson Sharon,Cook Mark,Cairns David A,Parrish Christopher

Funder

Cancer Research UK

Publisher

Elsevier BV

Reference30 articles.

1. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

2. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial;Cook;Lancet Haematol,2016

3. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation;Cavo;Blood,2011

4. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study;Kumar;Lancet Oncol,2014

5. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma;Moreau;N Engl J Med,2016